Evotec SE, DE0005664809

Evotec SE, DE0005664809

02.11.2022 - 07:33:27

EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day

starting at 11.00 am PDT (2.00 pm EDT, 7.00 pm CET) and a recording will be available on www.evotec.com the next day.About Dr John Erickson The son of a NASA engineer, Dr Erickson has always had a natural curiosity and passion for innovation. Dr Erickson received a BA in Biology and Chemistry from Amherst College and a MS in Chemical Engineering Practice and PhD in Chemical Engineering from MIT. He initially worked in industrial enzymology at Rh?ne-Poulenc before joining the biopharmaceutical industry. After joining GSK, he held a variety of roles in process development, project management, and manufacturing over 29 years. One of the highlights of that time was working with other industry colleagues on the A-mAb case study. Most recently, Dr Erickson served as Vice President, Biopharmaceutical and Steriles Manufacturing Science and Technology, where he was responsible for scientific oversight and support for commercial biopharmaceutical drug substance and sterile fill/finish of biopharmaceuticals and small molecules. Dr Erickson started a consulting company in 2019. He has been consulting for the National Institute for Innovation in Manufacturing Biopharmacuticals (?NIIMBL?), a public/private partnership, since 2019 as a Senior Fellow and has been Acting Chief Technology Officer since 2020. At NIIMBL he applies his perspective and extensive industry experience to help ensure that NIIMBL investments are aligned with current industry needs; support the management of a portfolio of impactful projects; and help lead technology initiatives and projects that will benefit the biopharmaceutical manufacturing ecosystem.ABOUT JUST ? EVOTEC BIOLOGICS Just ? Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just ? Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com. ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company?s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this ?Data-driven R&D Autobahn to Cures? for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company?s 16 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn. FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec?s securities. Words such as ?anticipate,? ?believe,? ?could,? ?estimate,? ?expect,? ?intend,? ?may,? ?might,? ?plan,? ?potential,? ?should,? ?target,? ?would? and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec?s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec?s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Media Contact Evotec SE: Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com Hinnerk Rohwedder, Senior Specialist Corporate Communications, Tel.: +49.(0)151 4070-4843, hinnerk.rohwedder@evotec.comIR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

02.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg

Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1476685 ? End of News EQS News Service


@ dgap.de